PHI Americas 2026 moves beyond the traditional trade show format to create a premium, content-first experience specifically centered around the contract development and manufacturing ecosystem. The event provides specialized focus on contract manufacturing partners, delivering programming, networking, and content with maximum relevance and business value to…
The complexity of the global pharma industry requires collaboration across the industry to drive sustainability efforts. In this fast-paced session, we will provide an overview of …
Opening chair remarks for the Track 1 - US Insights track.
For more than two decades at the FDA, Dr. Richard Pazdur stood at the center of drug regulation as Director of the Center for Drug Evaluation and Research and the Oncology Center o…
The pharmaceutical industry faces its most dramatic supply chain restructuring in decades. With U.S. tariffs escalating from 100% to a threatened 250% on branded pharmaceuticals, t…
For decades, U.S. pharmaceutical manufacturing operated within a globally optimized system built on scale, cost efficiency, technical capability, and regulatory alignment across ma…
The U.S. pharmaceutical industry is undergoing a pivotal transformation. Innovation in technology and therapeutics, evolving regulation, and shifting investment priorities are rede…
What does it mean when 25 companies show up — and 1 bet on three roles at once?
The numbers below are derived from the speakers, sponsors, and exhibitors on this page — cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.
The Triple-Threat
80% of the speakers carry senior titles — C-suite, Founder, VP, or Director-level.
Of 10 on the bill · classified by free-text title